Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

alexpitti Mar. 21 at 12:46 AM

$DCTH the ideaya data for their phase 3 PFS data on 130 patients with mUM is very likely coming next week

1 · Reply

alexpitti Mar. 20 at 4:35 PM

$DCTH april can't come soon enough, but delcath hates higher rates

0 · Reply

DragonAlgo Mar. 20 at 4:48 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-03-20 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $0.07 Stop: $0.05 TP1: $0.09 TP2: $0.12 TP3: $0.17 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

alexpitti Mar. 20 at 12:20 AM

$DCTH there's this thing called nuclear war. And also a thing called conservative guidance which will likely be partially reversed in april with a solid beat

1 · Reply

arcuy Mar. 19 at 9:04 AM

$DCTH why such a discount on the price ?

2 · Reply

brunoq14 Mar. 19 at 1:46 AM

$DCTH Another REMS site. Is that #29? Oregon Health & Science University Hospital

0 · Reply

alexpitti Mar. 18 at 6:47 PM

sometimes these stocks have a little bump in the road and fall. and then some macro issue just exacerbates the selling to no end $DCTH $ABEO $STXS

1 · Reply

alexpitti Mar. 18 at 6:20 PM

$DCTH spoke with Gerard. I'm super bullish

2 · Reply

alp224 Mar. 17 at 12:38 AM

$DCTH After 10 years still hate this stock. They are so manipulative expect reversal split all the time

3 · Reply

brunoq14 Mar. 16 at 4:43 PM

$DCTH Schwab has actually upgraded their opinion of Delcath, improving the percentile rating from the low 90s to the high 70s. Still Underperform, but no longer a strong Sell.

1 · Reply

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Mar 2, 2026, 3:42 PM EST - 19 days ago

Delcath: Fundamentals Intact, Despite Share Price Weakness

Feb 26, 2026, 3:17 PM EST - 23 days ago

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 8:00 AM EST - 23 days ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 7 weeks ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 21, 2026, 4:01 PM EST - 2 months ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 12:22 PM EST - 2 months ago

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Jan 9, 2026, 8:05 AM EST - 2 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Dec 31, 2025, 8:00 AM EST - 2 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 3 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Nov 20, 2025, 4:01 PM EST - 4 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 18, 2025, 8:00 AM EST - 4 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 13, 2025, 8:30 AM EST - 4 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 4 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 2:15 PM EST - 4 months ago

Delcath: Temporary Headwinds Are No Cause For Concern

Nov 4, 2025, 5:16 PM EST - 4 months ago

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 4 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 20, 2025, 5:05 PM EDT - 5 months ago

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Oct 20, 2025, 3:06 PM EDT - 5 months ago

Delcath: Large Upside With Limited Downside Risk

Oct 18, 2025, 4:15 PM EDT - 5 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 5 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 6 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Aug 19, 2025, 8:30 AM EDT - 7 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 3:06 PM EDT - 8 months ago

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 8:00 AM EDT - 8 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jun 12, 2025, 8:36 AM EDT - 10 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

May 22, 2025, 7:00 AM EDT - 10 months ago

Delcath Systems Issues Full Year 2025 Guidance

May 18, 2025, 8:25 AM EDT - 10 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 15, 2025, 4:30 PM EDT - 11 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 11 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 10:55 AM EDT - 11 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 11 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 2, 2025, 11:49 AM EDT - 1 year ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 2:17 PM EST - 1 year ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

alexpitti Mar. 21 at 12:46 AM

$DCTH the ideaya data for their phase 3 PFS data on 130 patients with mUM is very likely coming next week

1 · Reply

alexpitti Mar. 20 at 4:35 PM

$DCTH april can't come soon enough, but delcath hates higher rates

0 · Reply

DragonAlgo Mar. 20 at 4:48 AM

0 · Reply

alexpitti Mar. 20 at 12:20 AM

$DCTH there's this thing called nuclear war. And also a thing called conservative guidance which will likely be partially reversed in april with a solid beat

1 · Reply

arcuy Mar. 19 at 9:04 AM

$DCTH why such a discount on the price ?

2 · Reply

brunoq14 Mar. 19 at 1:46 AM

$DCTH Another REMS site. Is that #29? Oregon Health & Science University Hospital

0 · Reply

alexpitti Mar. 18 at 6:47 PM

sometimes these stocks have a little bump in the road and fall. and then some macro issue just exacerbates the selling to no end $DCTH $ABEO $STXS

1 · Reply

alexpitti Mar. 18 at 6:20 PM

$DCTH spoke with Gerard. I'm super bullish

2 · Reply

alp224 Mar. 17 at 12:38 AM

$DCTH After 10 years still hate this stock. They are so manipulative expect reversal split all the time

3 · Reply

brunoq14 Mar. 16 at 4:43 PM

$DCTH Schwab has actually upgraded their opinion of Delcath, improving the percentile rating from the low 90s to the high 70s. Still Underperform, but no longer a strong Sell.

1 · Reply

RemitTekram Mar. 16 at 2:09 PM

$DCTH Accumulate in low 9's and below is paying off.

1 · Reply

brunoq14 Mar. 16 at 10:42 AM

$DCTH https://clinicaltrials.gov/study/NCT06607458 Delcath Phase 2 Metastatic Colorectal Cancer with Liver Dominant Disease, update 03/13, now 10 sites recruiting of 26 prospective

0 · Reply

DragonAlgo Mar. 16 at 8:59 AM

0 · Reply

brunoq14 Mar. 13 at 6:53 PM

$DCTH https://clinicaltrials.gov/study/NCT06875128. We have an update (03/13) for Delcath's Phase 2 trial for patients with metastatic breast cancer with liver dominant disease. There are now two sites of a prospective 15: Moffitt in Florida and Ohio State. Both sites are recruiting.

0 · Reply

DragonAlgo Mar. 13 at 5:01 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-03-20 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $0.07 Stop: $0.05 TP1: $0.09 TP2: $0.12 TP3: $0.17 Rules-based execution profile. 🔗 https://dragonalgo.com

0 · Reply

Dryrr Mar. 12 at 9:20 AM

$DCTH the double bottom into reversal? would be nice to see this going back to 13-16

0 · Reply

Slowhorses Mar. 11 at 6:45 AM

$DCTH when CFO buys you pay attention.

1 · Reply

DragonAlgo Mar. 11 at 5:40 AM

0 · Reply

biggercapital Mar. 10 at 6:17 PM

Increased $CLPT and $DCTH this morning.

1 · Reply

xcdvfxcvnbxxvsd Mar. 10 at 3:25 PM

$DCTH When approx. we expect the NCCN quideline revision favoring Hepzato, assuming it would happen? Does it take weeks or months or is it anyones quess?

1 · Reply

DragonAlgo Mar. 10 at 11:02 AM

0 · Reply

Humdinger1966 Mar. 9 at 8:33 PM

$DCTH Percutaneous Hepatic Perfusion Plus Ipi/Nivo Improves PFS in Uveal Melanoma - this is a summary of the Lancet article https://www.targetedonc.com/view/percutaneous-hepatic-perfusion-plus-ipi-nivo-improves-pfs-in-uveal-melanoma?fbclid=IwY2xjawQcC7BleHRuA2FlbQIxMABicmlkETBlR2FDZHFEUnExN2N5Yk5zc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHpndyZKdkCPty7kiPPNrSn5nJ3gHqYdhSJG5p8mjRd0msvQ1d9lPA3FOpUhU_aem_-4qdY9E5fGIvFFjz7qUN8Q

0 · Reply

Market Cap	325.92M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	134.00
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	517,800
Avg Vol	493,706
Day's Range	N/A - N/A
Shares Out	34.75M
Stochastic %K	10%
Beta	0.38
Analysts	Strong Sell
Price Target	$22.17